Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regenxbio (RGNX) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to 176.27%.

  • Regenxbio's EBIT Margin rose 802800.0% to 176.27% in Q3 2025 from the same period last year, while for Sep 2025 it was 96.04%, marking a year-over-year increase of 1955400.0%. This contributed to the annual value of 280.03% for FY2024, which is 170900.0% up from last year.
  • Regenxbio's EBIT Margin amounted to 176.27% in Q3 2025, which was up 802800.0% from 296.26% recorded in Q2 2025.
  • Over the past 5 years, Regenxbio's EBIT Margin peaked at 78.66% during Q4 2021, and registered a low of 408.8% during Q1 2024.
  • Over the past 5 years, Regenxbio's median EBIT Margin value was 242.14% (recorded in 2024), while the average stood at 230.81%.
  • Its EBIT Margin has fluctuated over the past 5 years, first crashed by -2629700bps in 2022, then skyrocketed by 4224300bps in 2025.
  • Quarter analysis of 5 years shows Regenxbio's EBIT Margin stood at 78.66% in 2021, then tumbled by -334bps to 184.31% in 2022, then plummeted by -56bps to 287.68% in 2023, then increased by 16bps to 242.14% in 2024, then grew by 27bps to 176.27% in 2025.
  • Its EBIT Margin was 176.27% in Q3 2025, compared to 296.26% in Q2 2025 and 13.62% in Q1 2025.